Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial

de Gramont, Aimery, Van Cutsem, Eric, Schmoll, Hans-Joachim, Tabernero, Josep, Clarke, Stephen, Moore, Malcolm J, Cunningham, David, Cartwright, Thomas H, Hecht, J Randolph, Rivera, Fernando, Im, Seock-Ah, Bodoky, György, Salazar, Ramon, Maindrault-Goebel, Frédérique, Shacham-Shmueli, Einat, Bajetta, Emilio, Makrutzki, Martina, Shang, Aijing, André, Thierry, Hoff, Paulo M · 2012 · The Lancet Oncology

Abstract

Background Bevacizumab improves the efficacy of oxaliplatin-based chemotherapy in metastatic colorectal cancer. Our aim was to assess the use of bevacizumab in combination with oxaliplatin-based chemotherapy in the adjuvant treatment of patients with resected stage III or high-risk stage II colon carcinoma. Methods Patients from 330 centres in 34 countries were enrolled into this phase 3, open-label randomised trial. Patients with curatively resected stage III or high-risk stage II colon carcinoma were randomly assigned (1:1:1) to receive FOLFOX4 (oxaliplatin 85 mg/m(2), leucovorin 200 mg/m(2), and fluorouracil 400 mg/m(2) bolus plus 600 mg/m(2) 22-h continuous infusion on day 1; leucovorin 200 mg/m(2) plus fluorouracil 400 mg/m(2) bolus plus 600 mg/m(2) 22-h continuous infusion on day 2) every 2 weeks for 12 cycles; bevacizumab 5 mg/kg plus FOLFOX4 (every 2 weeks for 12 cycles) followed by bevacizumab monotherapy 7·5 mg/kg every 3 weeks (eight cycles over 24 weeks); or bevacizumab 7·5 mg/kg plus XELOX (oxaliplatin 130 mg/m(2) on day 1 every 2 weeks plus oral capecitabine 1000 mg/m(2) twice daily on days 1-15) every 3 weeks for eight cycles followed by bevacizumab monotherapy 7·5 mg/kg every 3 weeks (eight cycles over 24 weeks). Block randomisation was done with a central interactive computerised system, stratified by geographic region and disease stage. Surgery with curative intent occurred 4-8 weeks before randomisation. The primary endpoint was disease-free survival, analy…

Overview

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(12)70509-0

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 39 references

Cited by

See all 529

Metadata

Authors
de Gramont, A., Van Cutsem, E., Schmoll, H.-J., Tabernero, J., Clarke, S., Moore, M. J., Cunningham, D., Cartwright, T. H., Hecht, J. R., Rivera, F., Im, S.-A., Bodoky, G., Salazar, R., Maindrault-Goebel, F., Shacham-Shmueli, E., Bajetta, E., Makrutzki, M., Shang, A., André, T., & Hoff, P. M.
Affiliations
  • University Hospital in Halle (DE)
  • Universitat Autònoma de Barcelona (ES)
  • The University of Sydney (AU)
  • University of Toronto (CA)
  • Royal Marsden Hospital (GB)
  • University of California, Los Angeles (US)
  • Marqués de Valdecilla University Hospital (ES)
  • Seoul National University Hospital (KR)
  • F. Hoffmann-La Roche AG (CH)
  • Hôpital Saint-Antoine (FR)
  • Universidade de São Paulo (BR)
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2012-12
Volume
13
Issue
12
Pages
1225-1233
ISSN
1470-2045 (ISSN-L)
OpenAlex
W2098499757
Cited by
529
References
39
Citations by year
2026: 14 · 2025: 16 · 2024: 20 · 2023: 27 · 2022: 21 · 2021: 35 · 2020: 49 · 2019: 53 · 2018: 41 · 2017: 49 · 2016: 56 · 2015: 53 · 2014: 49 · 2013: 43 · 2012: 3
FWCI
23.39
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders
Genentech
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Keywords
bevacizumab, oxaliplatin, adjuvant chemotherapy, colon cancer, FOLFOX4, XELOX, capecitabine, disease-free survival, recurrence-free survival, anti-VEGF therapy, leucovorin
MeSH terms
Bevacizumab, Capecitabine, Oxaliplatin, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Colonic Neoplasms, Deoxycytidine, Female, Fluorouracil, Humans, Infusions, Intravenous, Male, Middle Aged, Organoplatinum Compounds, Oxaloacetates, Chemotherapy, Adjuvant, Young Adult, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. https://app.cochat.ai/papers/10.1016/s1470-2045(12)70509-0
The paper
de Gramont, A., Van Cutsem, E., Schmoll, H.-J., Tabernero, J., Clarke, S., Moore, M. J., Cunningham, D., Cartwright, T. H., Hecht, J. R., Rivera, F., Im, S.-A., Bodoky, G., Salazar, R., Maindrault-Goebel, F., Shacham-Shmueli, E., Bajetta, E., Makrutzki, M., Shang, A., André, T., & Hoff, P. M. (2012). Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(12)70509-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.